Targeted Therapies in Autoimmune and Inflammatory Skin Disorders

摘要: The character of treatment for autoimmune diseases is dramatically changing due to the constant identification new targets and subsequent development corresponding agents. enormous efforts in identifying target structures are based on a substantially refined understanding underlying disorder. B cells symbolize this recent development, since they attract lot attention as key players dysregulation mechanisms. It has been appreciated that not restricted (auto) antibody dependent functions, but demonstrate various effects contributing complex procedures finally resulting clinical symptoms autoimmunity. Consequently, directly affecting cell function interfering with release, respectively, being developed evaluated their benefit. High need better therapeutic outcomes still exists many disorders, although major progress initial introduction biologic agents, at least such rheumatoid arthritis, psoriasis or pemphigus, made. can be expected additional monoclonal antibodies fusion proteins directed against newly identified well pharmacologically improved compounds existing will brought clinic. Translational research decision some agents move application mainly preclinical, means animal, studies. disappointing experience cases results from animal studies poorly predicted successful humans. Thus, factors considered future include deeper knowledge pathogenic mechanisms, valuable biomarkers assessing efficacy safety more defined characterization optimum paradigms most appropriate patient populations use